Literature DB >> 2154348

A complex component modulating immune-deficient cells in leprosy patients leading to loss of viability of Mycobacterium leprae--a possible vaccine.

J Marolia1, P Robinson, P R Mahadevan.   

Abstract

Macrophages from peripheral blood of leprosy patients, both multi-bacillary and paucibacillary are unable to kill phagocytosed Mycobacterium leprae due to their inability to produce superoxide (O2-) and hydroxyl radicals (OH.). The macrophages from healthy individuals are able to kill M. leprae along with release of O2- and OH. radicals. The deficiency in the macrophages of both types of leprosy patients is removed by activation of these cells when exposed to a culture supernatant obtained after stimulation of peripheral blood mononuclear cells from the same patients with delipidified cell components of M. leprae which are most likely cell wall proteins. The activation of macrophages also leads to recognition of whole live M. leprae as an antigen by cells from lepromatous patients. This activation of the phagocytes by delipidified cell components is blocked by cyclosporin A, indicating the possible role of several steps involved in immune activation of cells. The observations thus indicate the significant ability of delipidified cell components to eliminate the deficiencies in the macrophages from leprosy patients and restore them to behave like the cells from healthy individuals. Considering all these, it is suggested that delipidified cell components could be potential modulators, and are probably capable of functioning as a vaccine for leprosy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154348      PMCID: PMC1534713          DOI: 10.1111/j.1365-2249.1990.tb05119.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Ultrastructural and chemical studies on wall-deficient forms, spheroplasts and membrane vesicles from Mycobacterium aurum.

Authors:  N Rastogi; H L David
Journal:  J Gen Microbiol       Date:  1981-05

2.  Killing of Mycobacterium microti by immunologically activated macrophages.

Authors:  L Walker; D B Lowrie
Journal:  Nature       Date:  1981-09-03       Impact factor: 49.962

3.  Superoxide production in pulmonary alveolar macrophages and killing of BCG by the superoxide-generating system with or without catalase.

Authors:  M Ando; M Suga; M Sugimoto; H Tokuomi
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

4.  Biological defense mechanisms. Evidence for the participation of superoxide in bacterial killing by xanthine oxidase.

Authors:  B M Babior; J T Curnutte; R S Kipnes
Journal:  J Lab Clin Med       Date:  1975-02

5.  Toxic effect of the peroxidase-hydrogen peroxide-halide antimicrobial system on Mycobacterium leprae.

Authors:  S J Klebanoff; C C Shepard
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

6.  The effect of cytochalasin B on the superoxide production by alveolar macrophages obtained from normal rabbit lungs.

Authors:  M Sugimoto; S Higuchi; M Ando; S Horio; H Tokuomi
Journal:  J Reticuloendothel Soc       Date:  1982-02

7.  MYCOBACTERIUM LEPRAE IN MICE: MINIMAL INFECTIOUS DOSE, RELATIONSHIP BETWEEN STAINING QUALITY AND INFECTIVITY, AND EFFECT OF CORTISONE.

Authors:  C C SHEPARD; D H MCRAE
Journal:  J Bacteriol       Date:  1965-02       Impact factor: 3.490

8.  A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture.

Authors:  E Pick; Y Keisari
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide.

Authors:  C F Nathan; L H Brukner; S C Silverstein; Z A Cohn
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

10.  Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2.

Authors:  N Nogueira; G Kaplan; E Levy; E N Sarno; P Kushner; A Granelli-Piperno; L Vieira; V Colomer Gould; W Levis; R Steinman
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.